US judge ruling imminent on Sanofi-Aventis's bid for injunction on generic Lovenox
This article was originally published in Scrip
Executive Summary
A US federal judge has now heard arguments concerning Sanofi-Aventis's bid for an injunction blocking the sale of a generic version of Lovenox (enoxaparin sodium) based on the grounds that the US FDA improperly approved the ANDA from Sandoz (Novartis).